1
|
Gomes Neto A, Simão AFL, Miranda Sde P,
Mourão LT, Bezerra NP, Almeida PR and Ribeiro Rde A: Experimental
rat lung tumor model with intrabronchial tumor cell implantation.
Acta Cir Bras. 23:84–92. 2008. View Article : Google Scholar : PubMed/NCBI
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Sun S, Schiller JH and Gazdar AF: Lung
cancer in never smokers-a different disease. Nat Rev Cancer.
7:778–790. 2007. View
Article : Google Scholar : PubMed/NCBI
|
4
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D’Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Cancer Network.
8:740–801. 2010. View Article : Google Scholar
|
5
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wolinsky JB, Colson YL and Grinstaff MW:
Local drug delivery strategies for cancer treatment: Gels,
nanoparticles, polymeric films, rods, and wafers. J Control
Release. 159:14–26. 2012. View Article : Google Scholar
|
7
|
Ramasamy T, Ruttala HB, Gupta B, Poudel
BK, Choi HG, Yong CS and Kim JO: Smart chemistry-based nanosized
drug delivery systems for systemic applications: A comprehensive
review. J Control Release. 258:226–253. 2017. View Article : Google Scholar : PubMed/NCBI
|
8
|
Sokolova V and Epple M: Inorganic
nanoparticles as carriers of nucleic acids into cells. Angew Chem
Int Ed Engl. 47:1382–1395. 2008. View Article : Google Scholar
|
9
|
Sun TM, Du JZ, Yao YD, Mao CQ, Dou S,
Huang SY, Zhang PZ, Leong KW, Song EW and Wang J: Simultaneous
delivery of siRNA and paclitaxel via a ‘two-in-one’ micelleplex
promotes synergistic tumor suppression. ACS Nano. 5:1483–1494.
2011. View Article : Google Scholar : PubMed/NCBI
|
10
|
Henke RT, Haddad BR, Kim SE, Rone JD, Mani
A, Jessup JM, Wellstein A, Maitra A and Riegel AT: Overexpression
of the nuclear receptor coactivator AIB1 (SRC-3) during progression
of pancreatic adenocarcinoma. Clin Cancer Res. 10:6134–6142. 2004.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Liu MZ, Xie D, Mai SJ, Tong ZT, Shao JY,
Fu YS, Xia WJ, Kung HF, Guan XY and Zeng YX: Overexpression of AIB1
in nasopharyngeal carcinomas correlates closely with advanced tumor
stage. Am J Clin Pathol. 129:728–734. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kuang SQ, Liao L, Zhang H, Lee AV,
O’Malley BW and Xu J: AIB1/SRC-3 deficiency affects insulin-like
growth factor I signaling pathway and suppresses v-Haras-induced
breast cancer initiation and progression in mice. Cancer Res.
64:1875–1885. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Xu JM, Liao L, Ning C, Yoshida-Komiya H,
Deng C and O’Malley BW: The steroid receptor coactivator SRC-3
(p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth,
puberty, female reproductive function, and mammary gland
development. Proc Natl Acad Sci USA. 97:6379–6384. 2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
Ruttala HB, Ramasamy T, Madeshwaran T,
Hiep TT, Kandasamy U, Oh KT, Choi HG, Yong CS and Kim JO: Emerging
potential of stimulus-responsive nanosized anticancer drug delivery
systems for systemic applications. Arch Pharm Res. 41:111–129.
2018. View Article : Google Scholar
|
15
|
Gautam A, Densmore CL, Golunski E, Xu B
and Waldrep JC: Transgene expression in mouse airway epithelium by
aerosol gene therapy with PEI-DNA complexes. Mol Ther. 3:551–556.
2001. View Article : Google Scholar : PubMed/NCBI
|
16
|
Godbey WT, Wu KK and Mikos AG:
Poly(ethylenimine) and its role in gene delivery. J Control
Release. 60:149–160. 1999. View Article : Google Scholar : PubMed/NCBI
|
17
|
Goula D, Benoist C, Mantero S, Merlo G,
Levi G and Demeneix BA: Polyethylenimine-based intravenous delivery
of transgenes to mouse lung. Gene Ther. 5:1291–1295. 1998.
View Article : Google Scholar
|
18
|
Lehman CM and Frank EL: Laboratory
monitoring of heparin therapy: Partial thromboplastin time or
anti-Xa assay. Lab Med. 40:47–51. 2009. View Article : Google Scholar
|
19
|
Josephson L, Tung CH, Moore A and
Weissleder R: High-efficiency intracellular magnetic labeling with
novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem.
10:186–191. 1999. View Article : Google Scholar : PubMed/NCBI
|
20
|
Scheicher B, Schachner-Nedherer AL and
Zimmer A: Protamine-oligonucleotide-nanoparticles: Recent advances
in drug delivery and drug targeting. Eur J Pharm Sci. 75:54–59.
2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Yang X, Du H, Liu J and Zhai G: Advanced
nanocarriers based on heparin and its derivatives for cancer
management. Biomacromolecules. 16:423–436. 2015. View Article : Google Scholar
|
22
|
Ramasamy T, Tran TH, Choi JY, Cho HJ, Kim
JH, Yong CS, Choi HG and Kim JO: Layer-by-layer coated
lipid-polymer hybrid nanoparticles designed for use in anticancer
drug delivery. Carbohydr Polym. 102:653–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Ma G, Ren Y, Wang K and He JJ: SRC-3 has a
role in cancer other than as a nuclear receptor coactivator. Int J
Biol Sci. 7:664–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Colo GP, Rosato RR, Grant S and Costas MA:
RAC3 down-regulation sensitizes human chronic myeloid leukemia
cells to TRAIL-induced apoptosis. FEBS Lett. 581:5075–5081. 2007.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Sundaramoorthy P, Ramasamy T, Mishra SK,
Jeong KY, Yong CS, Kim JO and Kim HM: Engineering of
caveolae-specific self-micellizing anticancer lipid nanoparticles
to enhance the chemotherapeutic efficacy of oxaliplatin in
colorectal cancer cells. Acta Biomater. 42:220–231. 2016.
View Article : Google Scholar : PubMed/NCBI
|